iodine-131 metuximab

Iodine-131 metuximab is a radiolabeled murine monoclonal antibody fragment (Fab2 of IgG1) that targets the CD147 antigen (also known as HAb18G), which is overexpressed on hepatocellular carcinoma (HCC) cells. The drug consists of the antibody fragment metuximab conjugated to radioactive iodine-131. Upon binding to CD147 on tumor cells, the radioisotope emits beta particles that cause localized DNA damage and cell death through radiation-induced apoptosis or necrosis. This targeted radioimmunotherapy approach allows for selective destruction of cancerous tissue while minimizing harm to surrounding healthy cells. Developed primarily for the treatment of hepatocellular carcinoma, it has been approved and marketed in China under the brand name Licartin since 2006[2][3][5]. Clinical trials have demonstrated improved survival rates and reduced recurrence in HCC patients treated with this agent[3]. Common side effects include hematological toxicity and mild radiation sickness.

Brand names

Licartin

Other names

Iodine (131I) metuximab131I-MetuximabI-Metuximab